NEW YORK, July 23 - Viaken has partnered with e-science platform provider InforSense to market and distribute their large-scale genomic analysis and drug discovery platform, the companies announced Monday.

The platform, called the Kensington Discovery Edition, was developed by Copenhagen-based InforSense as networked-based software for data mining and analysis.

Terms of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.